In this randomized clinical trial, gefitinib plus chemotherapy significantly improved intracranial PFS, PFS, and OS compared to gefitinib alone in patients with untreated EGFR-mutated NSCLC brain metastases, and may be an optional first-line therapy for these patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.